Tumor-specific methylation analysis of HoxA9 in patients with ovarian cancer in phase II clinical trials with bevacizumab and tocotrienol chemotherapy revealed that HoxA9 methylation was increased after 1 cycle of chemotherapy (Thomsen et al., 2019). This evidence concerns the gene HOXA9 and neoplasm.